Release Date: January 30, 2026
Expiration Date: January 30, 2027
Activity Overview
Non–muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease with highly variable risks of recurrence and progression. Evolving diagnostic tools, shifting definitions of BCG-unresponsive disease, and ongoing therapeutic advancements have created new challenges in selecting and sequencing evidence-based treatment. This activity aims to clarify contemporary best practices and highlight practical approaches for optimizing NMIBC management across risk categories.
In this program, through a case-driven format, expert faculty review recent data, emerging therapies, and real-world considerations that influence clinical decision-making. The program emphasizes multidisciplinary coordination, treatment personalization, and strategies for balancing bladder preservation with oncologic control to improve outcomes for patients with NMIBC.
This educational activity is an archive of the live virtual symposium held on January 17, 2026.
Target Audience
This educational activity is directed toward urologists. Other health care professionals involved in managing patients with NMIBC will be invited to participate as well.
Learning Objectives
Upon successful completion of this activity, you should be better
prepared to:
- Evaluate key clinical trial data and mechanistic features of novel and emerging NMIBC therapies across risk groups
- Incorporate new treatment options into personalized NMIBC care plans using patient-, disease-, and system-level considerations
- Integrate real-world considerations—such as toxicity, tolerability, and care delivery—into NMIBC treatment planning
Archan Khandekar, MD
Assistant Professor, Urologic
Oncology
Desai Sethi Urology Institute (DSUI)
University of Miami Miller School of Medicine
University of Miami Health Systems
Miami, FL
Disclosures: Archan Khandekar, MD, has no relevant financial relationships with ineligible companies.
Wassim Kassouf, MD, CM, FRCSC
Stephen Jarislowsky Chair in
Urology
Professor of Urology, Department of Surgery
McGill University
Head, Urologic Oncology
McGill University Health Center
Montreal, Quebec, Canada
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Bayer, CG Oncology, EMD Serono, enGene, Ferring, Janssen, Knight Therapeutics, Merck, Pfizer, Photocure; Grant/Research Funding (to institution): CIHR, CRS; Executive Role: President, Canadian Urological Association; GU Surgical Co-Chair, Canadian Clinical Trials Group; GU Steering committee, NIH
Jen-Jane Liu, MD
Director of Urologic Oncology
Associate Professor, Department of Urology
Knight Cancer Institute
Oregon Health & Science
University
Portland, OR
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: enGene
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
